1
|
Hisada Y. Dysregulated hemostasis in acute promyelocytic leukemia. Int J Hematol 2024; 119:526-531. [PMID: 38341391 DOI: 10.1007/s12185-024-03708-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 12/26/2023] [Accepted: 01/04/2024] [Indexed: 02/12/2024]
Abstract
Acute promyelocytic leukemia (APL) is associated with a high incidence of early death, which occurs within 30 days of diagnosis. The major cause of early death in APL is severe bleeding, particularly intracranial bleeding. Although APL is known to be associated with activation of coagulation, hyperfibrinolysis, and thrombocytopenia, the precise mechanisms that cause bleeding have not yet been elucidated. I propose that a combination of four pathways may contribute to bleeding in APL: (1) tissue factor, (2) the urokinase plasminogen activator/urokinase plasminogen activator receptor, (3) the annexin A2/S100A100/tissue plasminogen activator, and (4) the podoplanin/C-type lectin-like receptor 2. A better understanding of these pathways will identify new biomarkers to determine which APL patients are at high risk of bleeding and allow the development of new treatments for APL-associated bleeding.
Collapse
Affiliation(s)
- Yohei Hisada
- UNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, 116 Manning Drive, 8004 Mary Ellen Jones Bldg, Campus Box #7035, Chapel Hill, NC, 27599, USA.
| |
Collapse
|
2
|
Dunn WG, Gu MS, Fabre MA, Cooper J, Nomdedeu JF, Koumas L, Nicolaou K, Chi J, Costeas P, Vassiliou GS. The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. Ann Hematol 2022; 101:443-445. [PMID: 33650061 PMCID: PMC8742812 DOI: 10.1007/s00277-021-04472-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Accepted: 02/18/2021] [Indexed: 10/28/2022]
Affiliation(s)
- William G Dunn
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK
- Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK
| | - Muxin S Gu
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK
| | - Margarete A Fabre
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK
- Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK
| | - Jonathan Cooper
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK
| | - Josep F Nomdedeu
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK
- Department of Haematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - Laura Koumas
- Center for the Study of Haematological Malignancies, Karaiskakio Foundation, Nicosia, Cyprus
| | - Katerina Nicolaou
- Center for the Study of Haematological Malignancies, Karaiskakio Foundation, Nicosia, Cyprus
| | - Jiangxiang Chi
- Center for the Study of Haematological Malignancies, Karaiskakio Foundation, Nicosia, Cyprus
| | - Paul Costeas
- Center for the Study of Haematological Malignancies, Karaiskakio Foundation, Nicosia, Cyprus.
- Cyprus Cancer Research Institute, Nicosia, Cyprus.
| | - George S Vassiliou
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK.
- Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK.
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
- Center for the Study of Haematological Malignancies, Karaiskakio Foundation, Nicosia, Cyprus.
- Cyprus Cancer Research Institute, Nicosia, Cyprus.
| |
Collapse
|
3
|
Zhao H, Sun J, Yan L, Jin B, Hou W, Cao F, Li H, Zhou J, Zhang Y. Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study. Ann Hematol 2021; 100:1473-1483. [PMID: 33893844 DOI: 10.1007/s00277-021-04533-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Accepted: 04/12/2021] [Indexed: 11/26/2022]
Abstract
Acute promyelocytic leukemia (APL) cells constitutively express a large amount of tissue factor (TF) antigen, most of which is present in the cytoplasm. Coagulopathy may persist after induction therapy. We evaluated the overall role of circulating microparticles (MPs) in coagulation activation in APL-associated coagulopathy before and during induction therapy. Eleven adult patients with ≥ World Health Organization's (WHO) grade 2 bleeding events and 11 sex- and age-matched healthy controls were selected. All patients received arsenic trioxide alone as induction therapy. MP-associated TF (MP-TF) activity and MP procoagulant activity (MP-PCA) and 12 coagulation- and anticoagulation-associated indexes were measured before, during, and after induction therapy. Correlation between MP-associated indexes and the other 12 indexes was analyzed in patients. The MP-TF activity was negligible in controls, whereas it markedly increased in patients, dropped rapidly after treatment, and returned to normal at the end of induction therapy. The MP-PCA was similar between patients and controls. The correlation analysis revealed that TF-bearing MPs in patients mainly originated from APL cells. Partially differentiated APL cells could also release TF-bearing MPs, and the higher the degree of APL cell differentiation, the lower the ability of APL cells to release TF-bearing MPs. MP-TF was the main source of active TF in plasma and an important contributor for the coagulation activation in APL-associated coagulopathy. It was MPs released by APL cells/partially differentiated APL cells that served as the vehicle to transfer the large amount of TF to plasma to activate coagulation.
Collapse
Affiliation(s)
- Hongli Zhao
- Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
- Department of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
| | - Jiayue Sun
- Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
| | - Liru Yan
- Department of Carders Outpatient Service, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
| | - Bo Jin
- Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
| | - Wenyi Hou
- Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
| | - Fenglin Cao
- Department of Central Laboratory, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, 150001, People's Republic of China
| | - Haitao Li
- Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
| | - Jin Zhou
- Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China
- Department of Central Laboratory, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, 150001, People's Republic of China
| | - Yingmei Zhang
- Department of Central Laboratory, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, 150001, People's Republic of China.
| |
Collapse
|
4
|
Wanitpongpun C, Utchariyaprasit E, Owattanapanich W, Tantiworawit A, Rattarittamrong E, Niparuck P, Puavilai T, Julamanee J, Saelue P, Chanswangphuwana C, Polprasert C, Nakhakes C, Limvorapitak W, Kanitsap N, Prayongratana K, Sriswasdi C. Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG). Clin Lymphoma Myeloma Leuk 2021; 21:e635-e643. [PMID: 33926829 DOI: 10.1016/j.clml.2021.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 03/10/2021] [Accepted: 03/15/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND Acute myeloid leukemia (AML) is a common, challenging hematologic malignancy worldwide. Thai data on its characteristics and outcomes have never been systematically reported, to our knowledge. The objective of this study was to determine the clinical features and outcomes of Thai patients with AML. PATIENTS AND METHODS This was a prospective observational study of nine academic hospitals. Patients with newly diagnosed AML were invited to register online. RESULTS A total of 679 patients with AML were included. The presence of circulating peripheral blood blasts was correlated with a high white blood cell count. Acute promyelocytic leukemia (APL) had predominantly lower white blood cell counts and higher proportions without peripheral blood blasts compared with non-APL AML. Disseminated intravascular coagulation was commonly presented in APL (37.7%). Splenomegaly and normal platelet count were more frequently seen in patients with Philadelphia chromosome-positive AML. The median follow-up time for those who survived more than 1 year was 28.0 months. One-year overall survival rates for non-APL AML and APL were 31.9% and 88.2%, respectively; 2-year overall survival rates were 29.6% and 88.2%, respectively. Hematopoietic stem cell transplantation could improve survival in non-APL AML. CONCLUSION APL should be considered despite absence of peripheral blood blast. This study demonstrates poor outcome of Thai AML and more research to improve outcomes are underway. Expanding access to hematopoietic stem cell transplantation should be considered in Thailand.
Collapse
Affiliation(s)
- Chinadol Wanitpongpun
- Hematology Unit, Department of Internal Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
| | - Eakkapol Utchariyaprasit
- Division of Hematology, Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Weerapat Owattanapanich
- Division of Hematology, Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Adisak Tantiworawit
- Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
| | | | - Pimjai Niparuck
- Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Teeraya Puavilai
- Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | - Pirun Saelue
- Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Chantiya Chanswangphuwana
- Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
| | - Chantana Polprasert
- Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
| | - Chajchawan Nakhakes
- Division of Hematology, Department of Medicine, Rajavithi Hospital, Bangkok, Thailand
| | - Wasithep Limvorapitak
- Division of Hematology, Department of Internal Medicine, Thammasat University, Pathumthani, Thailand
| | - Nonglak Kanitsap
- Division of Hematology, Department of Internal Medicine, Thammasat University, Pathumthani, Thailand
| | - Kannadit Prayongratana
- Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
| | - Chantrapa Sriswasdi
- Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
| |
Collapse
|
5
|
Kampa-Schittenhelm KM, Haverkamp T, Bonin M, Tsintari V, Bühring HJ, Haeusser L, Blumenstock G, Dreher ST, Ganief T, Akmut F, Illing B, Mau-Holzmann UA, Bonzheim I, Schleicher E, Vogel W, Schittenhelm MM. Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine 2020; 54:102678. [PMID: 32272438 PMCID: PMC7139116 DOI: 10.1016/j.ebiom.2020.102678] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 01/29/2020] [Accepted: 01/30/2020] [Indexed: 12/21/2022] Open
Abstract
Background Overriding the differentiation blockage in acute myeloid leukemia (AML) is the most successful mode-of-action in leukemia therapy – now curing the vast majority of patients with acute promyelocytic leukemia (APL) using all-trans retinoic acid (ATRA)-based regimens. Similar approaches in other leukemia subtypes, such as IDH1/2-mutated AML, are under active investigation. We herein present successful release of the differentiation blockage upon treatment with the natural (−)-Δ9-Tetrahydrocannabinol isomer dronabinol in vitro and in vivo. Methods Cellular maturation and differentiation were followed in two patients employing whole genome methylation profiling, proteome analyses, NGS deep sequencing and multispectral imaging flow cytometry. For functional studies lentiviral OGT knock-down in vitro and ex vivo cell models were created to evaluate proliferative, apoptotic and differentiating effects of OGT in acute leukemia. Findings In here, we provide molecular evidence that dronbinol is capable to override the differentiation blockage of acute leukemia blasts at the state of the leukemia-initiating clone. We further identify the O-linked β-N-acetyl glucosamine (O-GlcNAc) transferase (OGT) to be crucial in this process. OGT is a master regulator enzyme adding O-GlcNAc to serine or threonine residues in a multitude of target proteins. Aberrant O-GlcNAc modification is implicated in pathologies of metabolic, neurodegenerative and autoimme diseases as well as cancers. We provide evidence that dronabinol induces transcription of OGT via epigenetic hypomethylation of the transcription start site (TSS). A lentiviral OGT-knock out approach proves the central role of OGT exerting antileukemic efficacy via a dual-mechanism of action: High concentrations of dronabinol result in induction of apoptosis, whereas lower concentrations drive cellular maturation. Most intriguingly, overriding of the differentiation blockage of acute leukemia blasts is validated in vivo following two patients treated with dronabinol. Interpretation In conclusion, we provide evidence for overcoming the differentiation blockage in acute leukemia in subentities beyond promyelocytic and IDH1/2-mutated leukemia and thereby identify O-GlcNAcylation as a novel (drugable) field for future leukemia research. Funding Unrestricted grant support by the IZKF Program of the Medical Faculty Tübingen (MMS) and Brigitte Schlieben-Lange Program as well as the Margarete von Wrangell Program of the Ministry of Science, Research and the Arts, Baden-Württemberg, Germany (KKS) and Athene Program of the excellence initiative University of Tübingen (KKS).
Collapse
Affiliation(s)
- K M Kampa-Schittenhelm
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany.
| | | | - M Bonin
- Microarray Genechip Facility Tübingen and Institute for Medical Genetics and Applied Genomics, Germany
| | - V Tsintari
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany
| | - H J Bühring
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany
| | - L Haeusser
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany
| | - G Blumenstock
- Institute of Clinical Epidemiology and Applied Biometry, Eberhard Karls University Tübingen, Germany
| | - S T Dreher
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany
| | - T Ganief
- Proteome Center Tübingen at the University of Tübingen, Germany
| | - F Akmut
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany
| | - B Illing
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany
| | - U A Mau-Holzmann
- University Hospital Tübingen, Division of Cytogenetics, Institute for Medical Genetics and Applied Genomics, Germany
| | - I Bonzheim
- Institute of Pathology at the University Hospital Tübingen, Germany
| | - E Schleicher
- University Hospital Tübingen, Dept. of Diabetology, Endokrinology, Nephrology, Germany
| | - W Vogel
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany
| | - M M Schittenhelm
- University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany; Clinic of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), Switzerland
| |
Collapse
|
6
|
Yoshinari GH, Fassoni AC, Mello LF, Rego EM. Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia. PLoS One 2019; 14:e0221011. [PMID: 31415632 PMCID: PMC6695187 DOI: 10.1371/journal.pone.0221011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Accepted: 07/30/2019] [Indexed: 11/18/2022] Open
Abstract
Acute Promyelocytic Leukemia (APL) is a rare and potentially lethal condition in which risk-based therapy often leads to better outcomes. Because of its rarity and relatively high overall survival rate, prospective randomized trials to investigate alternative APL treatment schedules are challenging. Mathematical models may provide useful information in this regard. We collected clinical data from 38 patients treated for APL under the International Consortium on Acute Leukemia (ICAL) protocol and laboratory data during induction therapy. We propose a mathematical model that represents the dynamics of leukocytes in peripheral blood and the effect of ICAL treatment on the disease’s dynamics. We observe that our cohort presents demographic characteristics and clinical outcomes similar to previous clinical trials on APL. Over a follow-up period of 41.8 months, the relapse-free survival and overall survival at two years are both found to be 78.7%. For two selected patients, the model produces a good fit to the clinical data. Information such as the response to treatment and risk of relapse can be derived from the model, and this may assist in clinical practice and the design of clinical trials.
Collapse
Affiliation(s)
- Gerson Hiroshi Yoshinari
- Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
- * E-mail: (GHY); (EMR)
| | - Artur César Fassoni
- Instituto de Matemática e Computação, Universidade Federal de Itajubá, Itajubá, MG, Brazil
| | - Luis Fernando Mello
- Instituto de Matemática e Computação, Universidade Federal de Itajubá, Itajubá, MG, Brazil
| | - Eduardo M. Rego
- Faculdade de Medicina da Universidade de São Paulo and Center for Cell Based Therapy, University of São Paulo, São Paulo, SP, Brazil
- Divisão de Hematologia, LIM31, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
- * E-mail: (GHY); (EMR)
| |
Collapse
|
7
|
Hu J, Sun Q, Fang W, Wang Q. Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells. Cell Mol Biol (Noisy-le-grand) 2019; 65:97-100. [PMID: 31078158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 04/15/2019] [Accepted: 04/16/2019] [Indexed: 06/09/2023]
Abstract
To study the effect of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) combination treatment on apoptosis of acute promyelocytic leukemia cells (NB4), inflammation and prognosis. The effect of ATRA - ATO combination on the proliferation of NB4 was determined using MTT assay. Apoptosis of NB4 cells was assessed with TUNEL assay. The effect of ATRA-As2O3 combination on the expressions of IL-6 and TNF-α in NB4 cells was determined using ELISA kits, while its effect on the quality of life of 25 acute promyelocytic leukemia patients admitted to our hospital was scored, as an index of prognosis. The combination treatment with ATRA and ATO significantly inhibited the proliferation of NB4 cells and promoted their apoptosis, relative to the model group. In addition, the combination treatment reduced serum IL-6 and TNF-α levels in patients with acute promyelocytic leukemia, and improve their quality of life and survival. Combination treatment with ATRA and ATO significantly inhibits the proliferation of NB4 cells and promotes their apoptosis, and reduces inflammatory responses in patients with acute promyelocytic leukemia, while improving their quality of life and prognosis.
Collapse
Affiliation(s)
- Jiane Hu
- Department of Clinical Laboratory, Chongqing Three Gorges Central Hospital, Chongqing City, China
| | - Qiuyan Sun
- Department of Pharmacy, Chongqing Three Gorges Central Hospital, Chongqing City, China
| | - Wei Fang
- Department of Pharmacy, Chongqing Three Gorges Central Hospital, Chongqing City, China
| | - Qinglin Wang
- Department of Clinical Laboratory, Chongqing Three Gorges Central Hospital, Chongqing City, China
| |
Collapse
|
8
|
Bai Y, Shi M, Yang X, Zhang W, Yang R, Wei X, Wei X, Duan L, Wang C, Mi R, Waqas Ahmed HA, Huo L, Chen Y, Xu F, Wu D, Sun K. The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis. Leuk Res 2019; 79:34-37. [PMID: 30831481 DOI: 10.1016/j.leukres.2019.02.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 01/10/2019] [Accepted: 02/20/2019] [Indexed: 11/16/2022]
Abstract
Hemorrhage is the typical manifestation of APL-related coagulopathy while thrombosis is infrequently reported. In a retrospective analysis with 33 patients with hyperleukocytic APL, we found 6 out of 33 hyperleukocytic APL patients presented with thrombosis rather than hemorrhage. A notable feature in these high-risk APL patients with thrombosis is that there were no significant abnormalities in fibrinogen (FIB), prothrombin time (PT) and activated partial thromboplastin time (APTT). Compared with the normal ranges, both the high-risk APL patients with thrombosis and the high-risk APL patients with hemorrhage had a significant increase in fibrinogen degradation product (FDP) and d-dimer levels. However, the group with hemorrhage had noticeably higher plasma levels of FDP and d-dimer than the group with thrombosis. To find a close relationship between coagulation markers and the onset of thrombotic events in patients with high-risk APL, the potential effects of FDP/FIB and d-dimer/FIB ratios as risk markers were investigated. We demonstrated that FDP/FIB and d-dimer/FIB ratios in the patients with high-risk APL with thrombosis showed higher ratios than the normal range but significantly lower ratios than the patients with high-risk APL-related hemorrhage. Our data demonstrated that the alteration in FDP/FIB and d-dimer/FIB ratios have more significant relevance than the levels of FIB, FDP or d-dimer as potential factors for predicting thrombosis and may help with designing more appropriately risk-adapted treatment protocols or personalized therapy.
Collapse
Affiliation(s)
- Yanliang Bai
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Mingyue Shi
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Xiawan Yang
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Wanjun Zhang
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Ruyu Yang
- Department of Hematology, Zhengzhou University Nanyang Hospital and Nanyang Central Hospital, #312 Gongnong Road, Nanyang, Henan, 473000, China
| | - Xiuli Wei
- Department of Hematology, Xinxiang First People's Hospital, #63 Yiheng Street, Xinxiang, Henan, 453000, China
| | - Xudong Wei
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, China
| | - Lijuan Duan
- Department of Hematology, Zhengzhou University Nanyang Hospital and Nanyang Central Hospital, #312 Gongnong Road, Nanyang, Henan, 473000, China
| | - Chenghua Wang
- Department of Hematology, Xinxiang First People's Hospital, #63 Yiheng Street, Xinxiang, Henan, 453000, China
| | - Ruihua Mi
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, China
| | - Hafiz Abdul Waqas Ahmed
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Lei Huo
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Yuqing Chen
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Fangfang Xu
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China
| | - Depei Wu
- Department of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, Jiangsu, 215006, China
| | - Kai Sun
- Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China.
| |
Collapse
|
9
|
Abstract
The aim of this study was to identify risk factors for early death (ED) in acute promyelocitic leukemia (APL) patients.Clinical records of 49 APL patients who suffered ED were divided into 4 groups: death before treatment or within the first 3 days (immediate death; iED group), death during treatment at least 3 days after commencement (ED after treatment), low/intermediate risk, and high-risk groups.White blood cell (WBC) count, high-risk cases, prothrombin time (PT) prolongation, international society on thrombosis and hemostasis (ISTH) scores (P < .05), bleeding (P = .05), and death due to severe hemorrhage (P = .010) were higher in iED group than ED after treatment. And the time from onset to initial hospitalization or death was significantly shorter (P < .05) in iED patients. LDH level (P = .002), PT prolongation (P = .014), and incidence of grades 3 or 4 bleeding (P = .049) were higher in high-risk group than in ED and low/intermediate-risk groups, while the times from onset to the initial hospitalization or death were lower for ED patients in high-risk group (P = .037).We found that different types of EDs have different clinical features. A high WBC count contributes to the occurrence of more ED, which is usually not associated with delay of diagnosis and hospitalization. Current therapeutic strategies to reduce the incidence of ED in these cases are not adequate and will benefit from focused research attention.
Collapse
Affiliation(s)
- Fang Xu
- Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou
- Hematology Department, Mianyang Central Hospital, Mianyang, China
| | - Chunli Wang
- Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou
| | - Changxin Yin
- Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou
| | - Xuejie Jiang
- Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou
| | - Ling Jiang
- Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou
| | - Zhixiang Wang
- Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou
| | - Fanyi Meng
- Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou
| |
Collapse
|
10
|
Fratamico RS, Strickland KS, Uppal G, Abu-Khalaf M. A Case of Carcinocythemia: De Novo Hormone Receptor-positive Metastatic Breast Cancer Presenting With Circulating Tumor Cells Mimicking an Acute Leukemia. Clin Breast Cancer 2017; 18:e295-e298. [PMID: 28735676 DOI: 10.1016/j.clbc.2017.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 06/13/2017] [Accepted: 06/29/2017] [Indexed: 11/19/2022]
Affiliation(s)
- Roberto S Fratamico
- Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
| | - Kimberly S Strickland
- Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Guldeep Uppal
- Division of Hematopathology, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA
| | - Maysa Abu-Khalaf
- Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
11
|
Lee HJ, Kim DH, Lee S, Koh MS, Kim SY, Lee JH, Lee S, Oh SY, Han JY, Kim HJ, Kim SH. Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia. Korean J Intern Med 2015; 30:884-90. [PMID: 26552464 PMCID: PMC4642018 DOI: 10.3904/kjim.2015.30.6.884] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2013] [Revised: 01/06/2014] [Accepted: 10/31/2014] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND/AIMS This study investigated whether patients with acute promyelocytic leukemia (APL) truly fulfill the diagnostic criteria of overt disseminated intravascular coagulation (DIC), as proposed by the International Society on Thrombosis and Haemostasis (ISTH) and the Korean Society on Thrombosis and Hemostasis (KSTH), and analyzed which component of the criteria most contributes to bleeding diathesis. METHODS A single-center retrospective analysis was conducted on newly diagnosed APL patients between January 1995 and May 2012. RESULTS A total of 46 newly diagnosed APL patients were analyzed. Of these, 27 patients (58.7%) showed initial bleeding. The median number of points per patient fulfilling the diagnostic criteria of overt DIC by the ISTH and the KSTH was 5 (range, 1 to 7) and 3 (range, 1 to 4), respectively. At diagnosis of APL, 22 patients (47.8%) fulfilled the overt DIC diagnostic criteria by either the ISTH or KSTH. In multivariate analysis of the ISTH or KSTH diagnostic criteria for overt DIC, the initial fibrinogen level was the only statistically significant factor associated with initial bleeding (p = 0.035), but it was not associated with overall survival (OS). CONCLUSIONS Initial fibrinogen level is associated with initial presentation of bleeding of APL patients, but does not affect OS.
Collapse
Affiliation(s)
- Ho Jin Lee
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Dong Hyun Kim
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Seul Lee
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Myeong Seok Koh
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - So Yeon Kim
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Ji Hyun Lee
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Suee Lee
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Sung Yong Oh
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Jin Yeong Han
- Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Hyo-Jin Kim
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
| | - Sung-Hyun Kim
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
- Correspondence to Sung-Hyun Kim, M.D. Department of Internal Medicine, Dong-A University College of Medicine, 26 Daesingongwon- ro, Seo-gu, Busan 49201, Korea Tel: +82-51-240-2608 Fax: +82-51-246-5044 E-mail:
| |
Collapse
|
12
|
Zhang X, Qin N, Chen X, Guo S. The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain. Pak J Pharm Sci 2015; 28:1075-1078. [PMID: 26051726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
This test cultivated three groups of acute promyelocytic leukemia (APL) and NB4 cells in liquid in vitro, processed them with arsenic trioxide (ATO), daunorubicin (DNR), ATO+DNR respectively, and then set up blank control group. Apoptosis of cells in each group was observed using flow cytometry, procoagulant activity of APL and NB4 cells in each group was detected with recalcification time, and expressions of tissue factor (TF), thrombomodulin and annexin II of NB4 cells in each group were measured using ELISA method. The results showed that the apoptosis rate increased 4-8 times compared with blank control group after processing APL and NB4 cells with ATO and DNR; procoagulant activity decreased obviously; and expression of TF and annexin II of NB4 cells reduced significantly (P<0.05). We concluded that combination of ATO and DNR could promote APL and NB4 cell apoptosis effectively without aggravating blood coagulation disorders, which might improve coagulation function of APL by inhibiting coagulation and hyperfibrinolysis through reducing expression of TF and annexin II. This drug combination may be a safe and effective method in the treatment of APL of primary high white blood cells type.
Collapse
Affiliation(s)
- Xiaojuan Zhang
- Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China
| | - Na Qin
- Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China
| | - Xinghua Chen
- Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China
| | - Shuxia Guo
- Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China
| |
Collapse
|
13
|
Zheng X, Guo Y, Chen Y, Chen M, Lin Z, Wu Y, Chen Y. Knockdown of Adhesion-Regulating Molecule 1 Inhibits Proliferation in HL60 Cells. Acta Haematol 2015; 134:88-100. [PMID: 25896055 DOI: 10.1159/000369916] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 11/17/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND/AIMS Adhesion-regulating molecule 1 (ADRM1), a receptor located on the 26S proteasome, is upregulated in many solid cancers. However, little is known about its role in acute leukemia (AL). METHODS We determined ADRM1 expression levels in both untreated AL samples and leukemia cell lines using real-time polymerase chain reaction or Western blot analysis. Growth curves, colony formation assays, cell cycle and apoptosis analyses, cell migration and invasion assays and NF-κB p65 nuclear translocation assays via Western blotting were used to examine the biological behavior of HL60 cells and the underlying mechanism. RESULTS ADRM1 was upregulated in both untreated AL samples and leukemia cell lines. ADRM1 knockdown significantly suppressed HL60 cell proliferation (48.82 ± 12.58%) and colony formation and caused cell cycle arrest in the G0/G1 phase. Furthermore, we confirmed that ADRM1 knockdown suppressed p65 nuclear translocation. CONCLUSION Our study revealed that ADRM1 was overexpressed in AL, especially in CD34+ leukemia stem and progenitor cells. ADRM1 may play a role in AL via the proteasome-ubiquitin pathway by potentially sustaining the activation of NF-κB signaling.
Collapse
MESH Headings
- Antigens, CD34/metabolism
- Apoptosis
- Cell Line, Tumor
- Cell Movement
- Cell Proliferation
- G1 Phase
- Gene Expression Regulation, Neoplastic
- Gene Knockdown Techniques
- HL-60 Cells
- Humans
- Intracellular Signaling Peptides and Proteins
- Leukemia/blood
- Leukemia/metabolism
- Leukemia/pathology
- Leukemia/therapy
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/metabolism
- Leukemia, Promyelocytic, Acute/pathology
- Leukemia, Promyelocytic, Acute/therapy
- Leukocytes, Mononuclear/metabolism
- Leukocytes, Mononuclear/pathology
- Membrane Glycoproteins/antagonists & inhibitors
- Membrane Glycoproteins/genetics
- Membrane Glycoproteins/metabolism
- Neoplasm Proteins/antagonists & inhibitors
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- RNA Interference
- RNA, Small Interfering
- Resting Phase, Cell Cycle
- Tumor Cells, Cultured
- Tumor Stem Cell Assay
Collapse
Affiliation(s)
- Xiaohui Zheng
- Union Clinical Medical College, Fujian Medical University, Fujian Medical University Union Hospital, Fuzhou, PR China
| | | | | | | | | | | | | |
Collapse
|
14
|
Chendamarai E, Ganesan S, Alex AA, Kamath V, Nair SC, Nellickal AJ, Janet NB, Srivastava V, Lakshmi KM, Viswabandya A, Abraham A, Aiyaz M, Mullapudi N, Mugasimangalam R, Padua RA, Chomienne C, Chandy M, Srivastava A, George B, Balasubramanian P, Mathews V. Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS One 2015; 10:e0121912. [PMID: 25822503 PMCID: PMC4378855 DOI: 10.1371/journal.pone.0121912] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Accepted: 02/06/2015] [Indexed: 11/25/2022] Open
Abstract
There is limited data on the clinical, cellular and molecular changes in relapsed acute promyeloytic leukemia (RAPL) in comparison with newly diagnosed cases (NAPL). We undertook a prospective study to compare NAPL and RAPL patients treated with arsenic trioxide (ATO) based regimens. 98 NAPL and 28 RAPL were enrolled in this study. RAPL patients had a significantly lower WBC count and higher platelet count at diagnosis. IC bleeds was significantly lower in RAPL cases (P=0.022). The ability of malignant promyelocytes to concentrate ATO intracellularly and their in-vitro IC50 to ATO was not significantly different between the two groups. Targeted NGS revealed PML B2 domain mutations in 4 (15.38%) of the RAPL subset and none were associated with secondary resistance to ATO. A microarray GEP revealed 1744 genes were 2 fold and above differentially expressed between the two groups. The most prominent differentially regulated pathways were cell adhesion (n=92), cell survival (n=50), immune regulation (n=74) and stem cell regulation (n=51). Consistent with the GEP data, immunophenotyping revealed significantly increased CD34 expression (P=0.001) in RAPL cases and there was in-vitro evidence of significant microenvironment mediated innate resistance (EM-DR) to ATO. Resistance and relapse following treatment with ATO is probably multi-factorial, mutations in PML B2 domain while seen only in RAPL may not be the major clinically relevant cause of subsequent relapses. In RAPL additional factors such as expansion of the leukemia initiating compartment along with EM-DR may contribute significantly to relapse following treatment with ATO based regimens.
Collapse
Affiliation(s)
| | - Saravanan Ganesan
- Department of Haematology, Christian Medical College, Vellore, India
| | - Ansu Abu Alex
- Department of Haematology, Christian Medical College, Vellore, India
| | - Vandana Kamath
- Department of Transfusion Medicine and Immunohaematology, Christian Medical College, Vellore, India
| | - Sukesh C. Nair
- Department of Transfusion Medicine and Immunohaematology, Christian Medical College, Vellore, India
| | | | - Nancy Beryl Janet
- Department of Haematology, Christian Medical College, Vellore, India
| | - Vivi Srivastava
- Cytogenetics Unit, Christian Medical College, Vellore, India
| | | | - Auro Viswabandya
- Department of Haematology, Christian Medical College, Vellore, India
| | - Aby Abraham
- Department of Haematology, Christian Medical College, Vellore, India
| | | | | | | | - Rose Ann Padua
- UMR 1131 Institut d’Hématologie, Hôpital Saint Louis, I avenue Claude Vellefaux, 75010 Paris, France
| | - Christine Chomienne
- UMR 1131 Institut d’Hématologie, Hôpital Saint Louis, I avenue Claude Vellefaux, 75010 Paris, France
| | - Mammen Chandy
- Department of Haematology, Christian Medical College, Vellore, India
| | - Alok Srivastava
- Department of Haematology, Christian Medical College, Vellore, India
| | - Biju George
- Department of Haematology, Christian Medical College, Vellore, India
| | | | - Vikram Mathews
- Department of Haematology, Christian Medical College, Vellore, India
- * E-mail:
| |
Collapse
|
15
|
Matsushita T, Watanabe J, Honda G, Mimuro J, Takahashi H, Tsuji H, Eguchi Y, Kitajima I, Sakata Y. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res 2014; 133:772-81. [PMID: 24636871 DOI: 10.1016/j.thromres.2014.02.025] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Revised: 02/09/2014] [Accepted: 02/25/2014] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Patients with acute promyelocytic leukemia (APL) can develop disseminated intravascular coagulation (DIC) that results in life-threatening hemorrhagic complications. Studies regarding the safety and efficacy of thrombomodulin alfa (TM-α; recombinant human soluble thrombomodulin) in patients with APL and DIC are limited. MATERIALS AND METHODS A retrospective evaluation was performed on a cohort of 172 patients with APL from an open-label, multicenter, post-marketing surveillance study of TM-α. RESULTS Of the 172 patients, 31 were relapse/refractory APL patients, and 141 were newly diagnosed APL patients. Within the first 30 days, 24 patients (14.0%) died, and six of those deaths (3.5%) were due to hemorrhage. In total, 12 patients (7.0%) had severe hemorrhagic complications. Both the early death rate due to hemorrhage as well as the severe hemorrhage rate did not exceed those in some recent population-based studies of patients with APL. Forty-nine patients received TM-α prior to the initiation of antileukemic treatment, and one patient experienced hemorrhagic early death (ED), suggesting that early TM-α treatment appeared to result in a reduction in the hemorrhagic ED rate. Moreover, TM-α improved coagulopathy regardless of concomitant all-trans retinoic acid treatment. CONCLUSIONS This study confirmed the safety and efficacy of TM-α in daily clinical practice for patients with APL and DIC. TM-α appeared to reduce hemorrhagic early deaths due to DIC in patients with APL who were receiving antileukemic treatment.
Collapse
Affiliation(s)
- Tadashi Matsushita
- Department of Transfusion Medicine, Nagoya University Hospital, Aichi, Japan; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin(®) Injection, Japan.
| | | | - Goichi Honda
- ART Project, Asahi Kasei Pharma Corporation, Tokyo, Japan
| | - Jun Mimuro
- Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, School of Medicine, Tochigi, Japan; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin(®) Injection, Japan
| | - Hoyu Takahashi
- Department of Internal Medicine, Niigata Prefectural Kamo Hospital, Niigata, Japan; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin(®) Injection, Japan
| | - Hajime Tsuji
- Department of Blood Transfusion, Kyoto Prefectural University of Medicine, Kyoto, Japan; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin(®) Injection, Japan
| | - Yutaka Eguchi
- Critical and Intensive Care Medicine, Shiga University of Medical Science, Shiga, Japan; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin(®) Injection, Japan
| | - Isao Kitajima
- Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medical and Pharmaceutical Science, University of Toyama, Toyama, Japan; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin(®) Injection, Japan
| | - Yoichi Sakata
- Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, School of Medicine, Tochigi, Japan; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin(®) Injection, Japan
| |
Collapse
|
16
|
Schindhelm RK, Berends JC, Wondergem MJ. [A woman with shortness of breath and butterfly shaped cell nuclei]. Ned Tijdschr Geneeskd 2014; 158:A6759. [PMID: 24495371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A 53-year-old woman with respiratory discomfort came to the Emergency Department. The blood smear, made because of a new thrombocytopenia, showed leukocytes with butterfly-shaped nuclei and fine cytoplasmic granulation. The diagnosis 'microgranular variant of acute promyelocytic leukemia' was made.
Collapse
|
17
|
Affiliation(s)
- Livia T Hegerova
- Resident in Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic, Rochester, MN
| | | | | |
Collapse
|
18
|
Wang H, Xi S, Liu Z, Yang Y, Zheng Q, Wang F, Xu Y, Wang Y, Zheng Y, Sun G. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Environ Toxicol 2013; 28:267-275. [PMID: 23589229 DOI: 10.1002/tox.20717] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2010] [Revised: 12/30/2010] [Accepted: 01/06/2011] [Indexed: 06/02/2023]
Abstract
Although arsenic is effective in the treatment of acute promyelocytic leukemia (APL), as a well-known environmental toxicant, the side effects of arsenic treatment and arsenic methylation metabolism of the patients are rarely reported. In this manuscript, we investigated 23 APL patients treated with 10 mg arsenic trioxide daily, detected the arsenic metabolites in urine samples collected on the 0, 10th, and 20th day of arsenic treatment. At the same time, liver function and blood routine examination were also investigated in these APL patients. We found that, urinary monomethylated arsenic proportion (MMA%) increased, but dimethylated arsenic proportion (DMA%), the first methylation ratio (FMR) and the secondary methylation ratio (SMR) decreased with consecutive administration of arsenic trioxide. After adjustment for age impact, no statistical difference was observed in urinary arsenic concentrations and arsenic methylation capacity between male and female at the same treatment time point. During arsenic trioxide treatment of APL, transient elevation of serum aminotransferases was found in the blood samples, which indicated that liver injury occurred and probably reversible. Leukocytosis developed in 5 of the 23 patients with the administration of arsenic trioxide. No statistical difference was observed in the other blood routine examination parameters. These results demonstrated that the capacity of arsenic methylation decreased and transient liver injury occurred during arsenic trioxide treatment of APL, which indicated that the side effects of clinical arsenic treatment can not be ignored.
Collapse
Affiliation(s)
- Huihui Wang
- Department of Occupational and Environmental Health, School of Public Health, China Medical University, Shenyang, Liaoning, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Parovichnikova EN, Troitskaia VV, Sokolov AN, Kliasova GA, Galstian GM, Kuz'mina LA, Domracheva EV, Dvirnyk VN, Savchenko VG. [Treatment of adult patients with acute promyelocytic leukemia according to the AIDA protocol]. TERAPEVT ARKH 2013; 85:10-17. [PMID: 24137942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
AIM To give the results of an investigation conducted at the Hematology Research Center (HRC), Ministry of Health of the Russian Federation (MHRF), to treat adult patients with acute promyelocytic leukemia (APL) according to the AIDA protocol elaborated by Spanish investigators. SUBJECTS AND METHODS The investigation enrolled 33 patients diagnosed with APL verified by cytogenetic and molecular studies, who had been treated at the HRC, MHRF, in July 2009 to January 2012. The patients classified in the low-, intermediate-, and high-risk groups were 30, 46.7; and 23.3%, respectively. The analysis was made in January 2013. RESULTS The number of patients who achieved complete remission, as well as the mortality rates during remission induction were wholly comparable to those previously obtained when using the 7+3+ATRA protocol: 90.3 and 9.7%, respectively. One patient in remission died (3.6% mortality rate). The likelihood of recurrence in this investigation was high (21%), which was due to gross noncompliance with maintenance therapy. On examining the clearance of the malignant clone by FISH and polymerase chain reaction, a naturally chimeric transcript identified by a molecular study was statistically significantly more frequently revealed during postinduction therapy, which was associated with different sensitivity of the techniques. Comparison of changes in the disappearance of a chimeric marker for APL with the AIDA and 7+3+ARTA programs showed that the clearance of the malignant clone was much slower. CONCLUSION The AIDA program is a highly effective treatment protocol for patients with APL.
Collapse
|
20
|
Au WY, Fong BM, Tam S, Kwong YL. Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis. Ann Hematol 2012; 92:417-8. [PMID: 23053177 PMCID: PMC3567333 DOI: 10.1007/s00277-012-1576-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2012] [Accepted: 09/08/2012] [Indexed: 12/30/2022]
Affiliation(s)
- Wing-Yan Au
- Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China
| | - Bonnie M. Fong
- Department of Clinical Biochemistry, Queen Mary Hospital, Hong Kong, China
| | - Sidney Tam
- Department of Clinical Biochemistry, Queen Mary Hospital, Hong Kong, China
| | - Yok-Lam Kwong
- Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China
| |
Collapse
|
21
|
Zhou LL, Han Y, Zhu Q, Hu LP, Zhao SX, Zhu MQ, Dai L, Shen WH, Chen L, Wu DP. [Detection of tissue factor-positive microparticles and its clinical significance in the haemostatic disorder]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012; 20:937-940. [PMID: 22931659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Objective of this study was to detect the level of tissue factor-positive microparticles (TF(+)MP) by flow cytometry (FCM) and to analyze its clinical significance in the haemostatic disorder. TF(+) MP was detected by FCM using antibody CD142-PE in 25 cases of acute promyelocytic leukemia (APL), 20 cases of hemostatic diseases and 20 healthy adults as controls. The differences of TF(+) MP between various groups were determined. The results showed that the level of TF(+) MP in the patients with thrombotic complications was significantly higher than that in the healthy adults (P < 0.05). The TF(+) MP level was higher in the patient with APL than that in the healthy adults, especially in course before therapy (P < 0.01), but the difference was not statistically significant in the patient with APL after therapy and the healthy adults. Among these patient with APL, the level of TF(+) MP in the 18 patients who complicated with disseminated intravascular coagulation (DIC) was also higher than that in the healthy adults (P < 0.05), but the level of TF(+) MP in the other 7 patients who did not complicate with DIC was similar before and after treatment. It is concluded that the method of TF(+) MP detection by FCM is feasible and simple, it is useful for the diagnosis of thrombotic disorder, and helps evaluation for the prognosis of APL patient.
Collapse
Affiliation(s)
- Li-Li Zhou
- Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Malato A, Santoro A, Felice R, Magrin S, Turri D, Bica MG, Salemi D, Fabbiano F. High-risk acute promyelocytic leukemia with early differentiation syndrome: a therapeutic dilemma. Acta Haematol 2011; 127:60-2. [PMID: 22094378 DOI: 10.1159/000333427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2011] [Accepted: 09/13/2011] [Indexed: 11/19/2022]
Affiliation(s)
- Alessandra Malato
- U.O. di Ematologia con UTMO, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italia.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
de Figueiredo-Pontes LL, Assis PA, Santana-Lemos BAA, Jácomo RH, Lima ASG, Garcia AB, Thomé CH, Araújo AG, Panepucci RA, Zago MA, Nagler A, Falcão RP, Rego EM. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One 2011; 6:e26713. [PMID: 22053203 PMCID: PMC3203897 DOI: 10.1371/journal.pone.0026713] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2010] [Accepted: 10/03/2011] [Indexed: 11/19/2022] Open
Abstract
Promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) expression in acute promyelocytic leukemia (APL) impairs transforming growth factor beta (TGFβ) signaling, leading to cell growth advantage. Halofuginone (HF), a low-molecular-weight alkaloid that modulates TGFβ signaling, was used to treat APL cell lines and non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice subjected to transplantation with leukemic cells from human chorionic gonadotrophin-PML-RARα transgenic mice (TG). Cell cycle analysis using incorporated bromodeoxyuridine and 7-amino-actinomycin D showed that, in NB4 and NB4-R2 APL cell lines, HF inhibited cellular proliferation (P<0.001) and induced apoptosis (P = 0.002) after a 24-hour incubation. Addition of TGFβ revealed that NB4 cells were resistant to its growth-suppressive effects and that HF induced these effects in the presence or absence of the cytokine. Cell growth inhibition was associated with up-regulation of TGFβ target genes involved in cell cycle regulation (TGFB, TGFBRI, SMAD3, p15, and p21) and down-regulation of MYC. Additionally, TGFβ protein levels were decreased in leukemic TG animals and HF in vivo could restore TGFβ values to normal. To test the in vivo anti-leukemic activity of HF, we transplanted NOD/SCID mice with TG leukemic cells and treated them with HF for 21 days. HF induced partial hematological remission in the peripheral blood, bone marrow, and spleen. Together, these results suggest that HF has anti-proliferative and anti-leukemic effects by reversing the TGFβ blockade in APL. Since loss of the TGFβ response in leukemic cells may be an important second oncogenic hit, modulation of TGFβ signaling may be of therapeutic interest.
Collapse
MESH Headings
- Animals
- Blood Cell Count
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Gene Expression Regulation, Leukemic/drug effects
- Humans
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/metabolism
- Leukemia, Promyelocytic, Acute/pathology
- Mice
- Mice, SCID
- Oncogene Proteins, Fusion/metabolism
- Piperidines/pharmacology
- Protein Serine-Threonine Kinases/metabolism
- Quinazolinones/pharmacology
- Receptor, Transforming Growth Factor-beta Type II
- Receptors, Transforming Growth Factor beta/metabolism
- Signal Transduction/drug effects
- Smad3 Protein/metabolism
- Transforming Growth Factor beta/antagonists & inhibitors
- Transforming Growth Factor beta/genetics
- Transforming Growth Factor beta/metabolism
- Transforming Growth Factor beta/pharmacology
- Up-Regulation/drug effects
Collapse
Affiliation(s)
- Lorena L. de Figueiredo-Pontes
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Patricia A. Assis
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Bárbara A. A. Santana-Lemos
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Rafael H. Jácomo
- Hematology Division of the Department of Internal Medicine, Medical School of the University of Brasília, Brasília, Brazil
| | - Ana Sílvia G. Lima
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Aglair B. Garcia
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Carolina H. Thomé
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Amélia G. Araújo
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Rodrigo A. Panepucci
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Marco A. Zago
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Arnon Nagler
- Hematology Division and Cord Blood Bank, Chaim Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel
| | - Roberto P. Falcão
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Eduardo M. Rego
- Hematology Division of the Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
- * E-mail:
| |
Collapse
|
24
|
Alimoghaddam K, Ghavamzadeh A, Jahani M, Jalali A, Jorjani H, Iravani M, Hamidieh AA, Mousavi A, Bahar B, Behfar M, Derakhshandeh R, Rostami S. Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran. Arch Iran Med 2011; 14:332-334. [PMID: 21888457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Acute promyelocytic leukemia is a rare indication for hematopoietic stem cell transplantation. Usually it is indicated as consolidation of salvage regimens following relpase. Here we report our experience with stem cell transplantation in acute promyelocytic leukemia patients. METHODS Between 1989 and 2011, we performed 40 hematopoietic stem cell transplantation in first complete remission or relapsed acute promyelocytic leukemia patients. Median age of patients was 23.5 years. Patients received 11 autologous and 29 allogeneic hematopoietic stem cell transplantation from their HLA fully-matched sibling donors. Different conditioning regimens were applied. A total of 24 patients received hematopoietic stem cell transplantation who were in first complete remission and the remainder with a second or more complete remission. RESULTS Hematopoietic stem cell engraftment was observed in all cases. There were no deaths prior to 100 days after hematopoietic stem cell transplantation. Acute graft versus host disease was mild to moderate in the majority of patients, whereas it was grade III in 4 patients. Chronic graft versus host disease was extensive in 2 cases. With a 4-year median follow up, the relapse rate was 25%. A total of 26 patients are alive. Five year overall survival was 65.5% and 46.8% for allogeneic and autologous hematopoietic stem cell transplantation, respectively. CONCLUSION Hematopoietic stem cell transplantation is an acceptable treatment for acute promyelocytic leukemia. Although there is a statistical difference for overall survival between allogeneic or autologous hematopoietic stem cell transplantation, the choice between autologous or allogeneic transplantation needs to have reliable methods for the detection of molecular remission before hematopoietic stem cell transplantation as well as close, reliable follow up of patients with clinical and molecular parameters.
Collapse
MESH Headings
- Adolescent
- Adult
- Blood Cell Count
- Bone Marrow Examination
- Child
- Child, Preschool
- Disease-Free Survival
- Female
- Graft vs Host Disease/etiology
- Graft vs Host Disease/physiopathology
- Hematopoietic Stem Cell Transplantation/adverse effects
- Hematopoietic Stem Cell Transplantation/methods
- Histocompatibility
- Humans
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/physiopathology
- Leukemia, Promyelocytic, Acute/therapy
- Male
- Middle Aged
- Monitoring, Physiologic
- Patient Selection
- Recurrence
- Remission Induction
- Retrospective Studies
- Salvage Therapy
- Severity of Illness Index
- Transplantation, Autologous
- Transplantation, Homologous
- Treatment Outcome
Collapse
Affiliation(s)
- Kamran Alimoghaddam
- Hematology Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Lipaĭ NV. [Blood coagulation parameters in children with acute promyelocytic leukemia, their changes during all-trans retinoic acid treatment, and causes of hemorrhagic and thrombotic events]. Klin Lab Diagn 2011:29-32. [PMID: 21509985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The specific feature of acute promyelocytic leukemia (APL) is blood coagulation impairments that appear as thrombohemorrhagic disorders with a possible fatal outcome. The pathogenesis of bleeding in APL is due to the properties of leukemic promyelocytes; however, little is known about the causes of venous thrombosis in APL. This circumstance determined the objective of the investigation, which was to study the functional state of blood coagulation over time during treatment for APL and to reveal the causes of thromboses in children with this condition. There was a relationship of the Leiden mutation in patients with APL to the development of thrombosis (p = 0.009). Vein catheterization and puncture are other provoking factors of thrombosis.
Collapse
|
26
|
Zhou J, Shi J, Hou J, Cao F, Zhang Y, Rasmussen JT, Heegaard CW, Gilbert GE. Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost 2010; 8:773-82. [PMID: 20102487 DOI: 10.1111/j.1538-7836.2010.03763.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Acute promyelocytic leukemia (APL) frequently causes disseminated intravascular coagulation that can worsen with cytotoxic chemotherapy but improve with the therapeutic differentiating agents, all trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)). APL cells display tissue factor but the relationship of tissue factor and other procoagulant activity to phosphatidylserine (PS) exposure is largely unknown. METHODS Lactadherin, a milk protein with stereospecific binding to phosphatidyl-L-serine, was used as a probe for PS exposure on an immortalized APL cell line (NB4) and on the cells of eight patients with APL. PS exposure was evaluated with flow cytometry, confocal microscopy, coagulation assays, and purified prothrombinase and factor (F) Xase assays. RESULTS Plasma procoagulant activity of NB4 and APL cells increased approximately 15-fold after exposure to etoposide or daunorubicin and decreased 80% after treatment with ATRA or As(2)O(3). Procoagulant activity corresponded to exposed PS on viable APL cells. PS exposure decreased after treatment with ATRA or As(2)O(3) and increased after treatment with daunorubicin or etoposide. Excess lactadherin inhibited 80-85% of intrinsic FXase, FVIIa-tissue factor and prothrombinase activities on both NB4 cells and APL cells. Confocal microscopy identified membrane patches that stained with lactadherin, but not annexin V, demonstrating focal, low-level PS exposure. CONCLUSIONS PS is exposed on viable APL cells and is necessary for approximately 80% of procoagulant activity.
Collapse
Affiliation(s)
- J Zhou
- Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China.
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Carella AM, Antonucci G, Conte M, Di Pumpo M, Antonucci E, Ponziano E. A case of ischemic stroke in acute promyelocytic leukemia at initial presentation. Relevance of all-trans retinoic acid treatment. Cardiovasc Hematol Disord Drug Targets 2010; 10:1-6. [PMID: 20041837 DOI: 10.2174/187152910790780069] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2009] [Accepted: 12/24/2009] [Indexed: 05/28/2023]
Abstract
Acute promyelocytic leukemia (APL) is frequently associated, often from the earliest phases, with a life-threatening coagulation/bleeding syndrome; disseminated intravascular coagulation (DIC) is described in majority of patients. We report a case of 49-year-old male, without cardiovascular risk factors, who suddenly developed ischemic stroke and splenic infarction as presenting symptoms of APL and related DIC. The patient was immediately treated with all-trans retinoic acid (ATRA) and the alterations of hemocoagulation parameters promptly returned in normal range. The coagulation/bleeding syndrome of the onset of APL is associated with high mortality; both diagnostic and therapeutic approaches require special and timely consideration of this condition. Treatment with ATRA is essential.
Collapse
Affiliation(s)
- Angelo M Carella
- Internal Medicine Department of T. Masselli-Mascia Hospital - San Severo (Fg), Italy.
| | | | | | | | | | | |
Collapse
|
28
|
Kato A. [Disseminated intravascular coagulation in malignant neoplasms]. Rinsho Ketsueki 2010; 51:37-43. [PMID: 20134138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
|
29
|
Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 2009; 95:853-4. [PMID: 20015875 DOI: 10.3324/haematol.2009.017962] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
30
|
Mehta JP, Shaib FH. Spurious hypoxemia. J Ky Med Assoc 2009; 107:483-484. [PMID: 20067200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Affiliation(s)
- Jinesh P Mehta
- Division of Pulmonary, Critical Care and Sleep Disorders, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
| | | |
Collapse
|
31
|
Kondo M, Nakabayashi Y, Sugiyama A, Tominaga T, Shinohara K. A case of acute promyelocytic leukemia showing transient thrombocytosis caused by increased interleukin-6 and thrombopoietin after treatment with all-trans retinoic acid and chemotherapy. Gan To Kagaku Ryoho 2009; 36:827-830. [PMID: 19461187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
A patient with acute promyelocytic leukemia(APL)treated with all-trans retinoic acid(ATRA)and chemotherapy for remission induction developed marked thrombocytosis after bone marrow recovery. Thrombocytosis also occurred after post remission chemotherapies, although the degree of thrombocytosis gradually decreased. During thrombocytosis, plasma levels of interleukin-6(IL-6)were elevated while those of thrombopoietin(TPO)were not elevated. However, the plasma level of TPO was markedly elevated at the nadir after post remission chemotherapy. These findings suggest that in APL patients, thrombocytosis after treatment with ATRA and or chemotherapy may be caused by increased plasma levels of both of IL-6 and TPO.
Collapse
Affiliation(s)
- Manabu Kondo
- Division of Hematology, Department of Medicine, Yamaguchi Prefectural Medical Center, Yamaguchi, Japan
| | | | | | | | | |
Collapse
|
32
|
Yamane A, Tsukamoto N, Saitoh T, Uchiumi H, Handa H, Karasawa M, Nojima Y, Murakami H. Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Intern Med 2009; 48:1691-4. [PMID: 19755776 DOI: 10.2169/internalmedicine.48.2358] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Although all-trans retinoic acid (ATRA) is widely used in acute promyelocytic leukemia (APL), there is little data as to whether or not ATRA is useful for patients with liver and renal failure. A 63-year-old APL patient, complicated by Child-Pugh class A liver cirrhosis and chronic renal failure (creatinine 3.2 mg/dL), was successfully treated with 45 mg/m(2)/day of ATRA. With three courses of chemotherapy, complete remission has been maintained for four years in this patient. Serum trough and maximum ATRA concentration, and the area under the curve (AUC) were not elevated. These observations suggest that full-dose ATRA therapy might be safely applicable to such a complicated case with APL.
Collapse
MESH Headings
- Antineoplastic Agents/blood
- Antineoplastic Agents/pharmacokinetics
- Antineoplastic Agents/therapeutic use
- Humans
- Hypercalcemia/blood
- Hypercalcemia/complications
- Kidney Failure, Chronic/blood
- Kidney Failure, Chronic/complications
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/complications
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/metabolism
- Liver Cirrhosis/blood
- Liver Cirrhosis/complications
- Liver Failure/blood
- Liver Failure/complications
- Male
- Middle Aged
- Polycystic Kidney Diseases/blood
- Polycystic Kidney Diseases/complications
- Remission Induction
- Tretinoin/blood
- Tretinoin/pharmacokinetics
- Tretinoin/therapeutic use
Collapse
Affiliation(s)
- Arito Yamane
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Fu GH, Wang Y, Xi YH, Guo ZW, Liu XB, Bai SZ, Yang BF, Chen GQ. As2O3enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein. J Drug Target 2008; 13:235-43. [PMID: 16051535 DOI: 10.1080/10611860500207060] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Successful application of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) has been attracting worldwide interest, but the exact mechanism for the action of As2O3 remains somewhat obscure. In the present work, we show for the first time that As2O3 facilitates the DIDS-sensitive anion transport activity of band 3 protein in red blood cells (RBCs) isolated from normal adults and APL patients. To elucidate the effect of As2O3 on band 3 protein, constructs encoding the full length of the band 3 transmembrane domain (mdb3) and its C-terminal deletion forms were transfected into yeast cells by a yeast display system. The results demonstrate that deletion of the C-terminal 16 residues of mdb3 (mdb3-d16) does not affect anion transport activity of mdb3 or its sensitivity to DIDS, but decreases its sensitivity to As2O3 in the yeast cell. More intriguingly, the forced expression of intact mdb3 by transfection significantly induces cell apoptosis in HeLa cells, to a higher degree than in cells transfected with mdb3-d16 or empty vector. Expression of activated caspase 3 in HeLa cells also indicates that the C-terminal 16 residues are important for mdb3-mediated apoptosis in cells treated with As2O3. Our results provide the first evidence that As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein.
Collapse
Affiliation(s)
- Guo-Hui Fu
- Department of Pathophysiology, Rui-Jin Hospital, Shanghai Second Medical University (SSMU), Shanghai 200025, China.
| | | | | | | | | | | | | | | |
Collapse
|
34
|
He KL, Deora AB, Xiong H, Ling Q, Weksler BB, Niesvizky R, Hajjar KA. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. J Biol Chem 2008; 283:19192-200. [PMID: 18434302 PMCID: PMC2443646 DOI: 10.1074/jbc.m800100200] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2008] [Revised: 03/14/2008] [Indexed: 01/08/2023] Open
Abstract
The annexin A2 (A2) heterotetramer, consisting of two copies of A2 and two copies of S100A10/p11, promotes fibrinolytic activity on the surface of vascular endothelial cells by assembling plasminogen and tissue plasminogen activator (tPA) and accelerating the generation of plasmin. In humans, overexpression of A2 by acute promyelocytic leukemia cells is associated with excessive fibrinolysis and hemorrhage, whereas anti-A2 autoantibodies appear to accentuate the risk of thrombosis in patients with anti-phospholipid syndrome. Complete deficiency of A2 in mice leads to a lack of tPA cofactor activity, accumulation of intravascular fibrin, and failure to clear arterial thrombi. Within the endothelial cell, p11 is required for Src kinase-mediated tyrosine phosphorylation of A2, which signals translocation of both proteins to the cell surface. Here we show that p11 is expressed at very low levels in the absence of A2 both in vitro and in vivo. We demonstrate further that unpartnered p11 becomes polyubiquitinated and degraded via a proteasome-dependent mechanism. A2 stabilizes intracellular p11 through direct binding, thus masking an autonomous p11 polyubiquitination signal that triggers proteasomal degradation. This interaction requires both the p11-binding N-terminal domain of A2 and the C-terminal domain of p11. This mechanism prevents accumulation of free p11 in the endothelial cell and suggests that regulation of tPA-dependent cell surface fibrinolytic activity is precisely tuned to the intracellular level of p11.
Collapse
Affiliation(s)
- Kai-Li He
- Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York 10065, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Rajpurkar M, Alcasabas P, Warrier I, Valentini RP, Fassinger N, Frattarelli DAC, Ravindranath Y. Effect of dialysis on all trans retinoic acid levels in a child with acute promyelocytic leukemia and renal failure. Pediatr Blood Cancer 2007; 49:994-6. [PMID: 16609947 DOI: 10.1002/pbc.20844] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
All trans retinoic acid (ATRA) combined with chemotherapy has become the mainstay of treatment for patients with acute promyelocytic leukemia (APL). Renal dysfunction (RD) is commonly seen in patients with APL. We describe a patient with APL and multi-organ failure, who was on chronic veno-venous hemofiltration followed by hemodialysis (HD) and later peritoneal dialysis (PD), who received ATRA. ATRA levels were assessed as the body clearance of ATRA in children on HD and/or PD was unknown. Neither HD nor PD significantly affected ATRA levels, suggesting that dose modifications of ATRA may not be necessary for children with these forms of renal replacement therapy.
Collapse
Affiliation(s)
- Madhvi Rajpurkar
- Carman and Ann Adams Department of Pediatrics, Division of Hematology Oncology, Children's Hospital of Michigan, Detroit, Michigan 48201, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Zhu HH, Liu YR, Qin YZ, Jiang B, Shan FX, Wu SL, Yang PD, Zhao J, Lu DP. Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR. Chin Med J (Engl) 2007; 120:1803-1808. [PMID: 18028775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023] Open
Abstract
BACKGROUND Real-time quantitative RT-PCR (RQ-PCR) assay has become a vital tool to monitor residual disease of leukemia. However, the complexity and standardization of RQ-PCR should never be overlooked and the results should be interpreted cautiously in clinical conditions. We aimed to assess the methodology of RQ-PCR and its clinical applications in monitoring molecular kinetics of 36 newly diagnosed cases of acute promyelocytic leukemia patients with t (15; 17) from October 2004 to December 2005. METHODS All the TaqMan probe-based RQ-PCR reactions and analysis were performed on an ABI-PRISM 7,500 platform. The quantitation of PML-RARalpha transcripts was represented by the normalized quotient, that is, PML-RARalpha transcript copies divided by ABL transcript copies. According to induction therapy, the patients were classed into two groups: group 1 (n = 23), three-drug combination including arsenics, all-trans retinoic acid and mitoxantrone; and group 2 (n = 13), two-drug combination from all-trans retinoic acid, arsenics and mitoxantrone. RESULTS The sensitivity of RQ-PCR was 1 per 10(5) cells and 5 copies of the PML-RARalpha transcript could be reproducibly detected. No false positive results occurred in 40 non-acute promyelocytic leukemia samples. Optimal amplification efficiency could be attained, which was determined by the slope of the standard curves (slope: -3.2 - -3.7). The inter-assay and intra-assay variation coefficients of the method were 1.01% and 0.56% respectively. Although the time to attain hematological complete remission was similar in both groups, the time to achieve molecular remission of group 1 was significantly shorter than that of group 2 (61 days vs 75 days, P = 0.034). The rate of molecular remission within 70 days was higher in group 1 than in group 2 (75.00% vs 38.46%, P = 0.036). Compared with pretreatment, median reduction of the PML-RARalpha transcript before first consolidation therapy differed significantly between group 1 and group 2 (log scale, 3.15 vs 2.31, P = 0.024). Interestingly, we found that PML-RARalpha transcript levels temporarily increased in bone marrow (7 patients) and peripheral blood (22 patients) samples of patients during induction therapy in both groups. CONCLUSIONS The RQ-PCR assay is reliable for the detection of PML-RARalpha transcripts. Arsenics, all-trans retinoic acid and mitoxantrone triad induction treatment of acute promyelocytic leukemia is superior to two-drug combination induction therapy in terms of the molecular response.
Collapse
Affiliation(s)
- Hong-hu Zhu
- Institute of Hematology, Peking University People's Hospital, Beijing 100044, China
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
Annexins comprise a conserved family of proteins characterised by their ability to bind and order charged phospholipids in membranes, often in response to elevated intracellular calcium. The family members (there are at least 12 in humans) have become specialised over evolutionary time and are involved in a diverse range of cellular functions both inside the cell and extracellularly Although a mutation in an annexin has never been categorically proven to be the cause of a disease state, they have been implicated in pathologies as diverse as autoimmunity, infection, heart disease, diabetes and cancer. 'Annexinopathies' were first described by Jacob H. Rand to describe the pathological sequelae in two disease states, the overexpression of annexin 2 in a patients with a haemorrhagic form of acute promyelocytic leukaemia, and the under-expression of annexin 5 on placental trophoblasts in the antiphospholipid syndrome. In this chapter we will outline some of the more recent observations in regard to these conditions, and describe the involvement of annexins in some other major causes of human morbidity.
Collapse
Affiliation(s)
- M J Hayes
- Div of Cell Biology, University College London Institute of Ophthalmology, 11-43 Bath Street, London ECI V 9EL, UK
| | | | | | | |
Collapse
|
38
|
Au WY, Liu CL, Tam S, Fong BMW, Shek TW, Hui CK, Kwong YL. Oral arsenic trioxide therapy for acute promyelocytic leukemia before and after liver transplantation for hepatitis B virus-related liver failure. Ann Hematol 2007; 86:771-2. [PMID: 17571262 DOI: 10.1007/s00277-007-0318-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2007] [Accepted: 05/12/2007] [Indexed: 11/28/2022]
|
39
|
Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, San Miguel JF, González MG. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 2007; 92:315-22. [PMID: 17339180 DOI: 10.3324/haematol.10734] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND AND OBJECTIVES The detection of PML-RARalpha by real-time polymerase chain reaction (RQ-PCR) is becoming an important tool for monitoring minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL). However, its clinical value remains to be determined. Our aim was to analyze any associations between the risk of relapse and RQ-PCR results in different phases of treatment, comparing these data with those yielded by conventional qualitative reverse transcriptase-PCR. DESIGN AND METHODS Follow-up samples from 145 APL patients treated with the PETHEMA protocols were evaluated by the RQ-PCR protocol (Europe Against Cancer program) and by the RT-PCR method (BIOMED-1 Concerted Action). Hematologic and molecular relapses and relapse-free survival were recorded. We then looked for associations between relapse risk and RQ-PCR results. RESULTS After induction therapy, no association was found between positive RQ-PCR results and relapse. The PCR result here did not imply any change in the scheduled therapy. After the third consolidation course, two out of three cases with positive RQ-PCR relapsed in contrast to 16 out of 119 (13%) patients with negative RQ-PCR. During maintenance therapy and out-of treatment, all patients with >10 PML-RARalpha normalized copy number (NCN) (n=19) relapsed while all patients with <1 NCN at the end of the study remained in hematologic remission (p<0.0001). In the intermediate group (NCN 1-10) (n=18), the relapse-free survival at 5 years was 60%. Hematologic relapses were predicted if a positive RQ-PCR result had been obtained in a follow-up sample within the previous 4 months. INTERPRETATION AND CONCLUSIONS Based on the information provided by RQ-PCR in samples obtained after the end of consolidation and subsequently, a relapse risk stratification could be established for APL patients. This stratification divides patients into three groups: those at high risk of relapse, those with an intermediate risk and those with a low risk of relapse.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Child
- Clinical Trials as Topic/statistics & numerical data
- Computer Systems
- DNA, Complementary/genetics
- Disease-Free Survival
- Drug Monitoring
- Female
- Follow-Up Studies
- Gene Dosage
- Humans
- Idarubicin/administration & dosage
- Kaplan-Meier Estimate
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukocyte Count
- Male
- Middle Aged
- Multicenter Studies as Topic/statistics & numerical data
- Neoplasm, Residual
- Oncogene Proteins, Fusion/blood
- Oncogene Proteins, Fusion/genetics
- Polymerase Chain Reaction/methods
- Predictive Value of Tests
- RNA, Messenger/blood
- RNA, Neoplasm/blood
- Recurrence
- Remission Induction
- Risk Assessment
- Salvage Therapy
- Sensitivity and Specificity
- Survival Analysis
- Tretinoin/administration & dosage
Collapse
Affiliation(s)
- Carlos Santamaría
- Departament of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
| | | | | | | | | | | | | | | |
Collapse
|
40
|
MESH Headings
- Animals
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Arsenic Trioxide
- Arsenicals/administration & dosage
- Arsenicals/pharmacology
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Clinical Trials as Topic
- Computer Systems
- Disease Management
- Drug Monitoring
- Hematopoietic Stem Cells/drug effects
- Humans
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukocyte Count
- Mice
- Multicenter Studies as Topic
- Oncogene Proteins, Fusion/blood
- Oncogene Proteins, Fusion/genetics
- Oncogene Proteins, Fusion/physiology
- Oxides/administration & dosage
- Oxides/pharmacology
- Polymerase Chain Reaction/methods
- Predictive Value of Tests
- Recurrence
- Sensitivity and Specificity
- Transfection
- Tretinoin/administration & dosage
- Tretinoin/pharmacology
Collapse
|
41
|
Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M, Rivas C, Alvarez C, González San Miguel JD, Brunet S, Tomás JF, Tormo M, Sayas MJ, Sánchez Godoy P, Colomer D, Bolufer P, Sanz MA. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007; 21:446-52. [PMID: 17205057 DOI: 10.1038/sj.leu.2404501] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To determine prognosis of acute promyelocytic leukemia (APL) failing to front-line therapy with all-trans retinoic acid (ATRA) and anthracyclines, outcome of 52 patients (32 M/20 F; age: 37, 3-72) included in PETHEMA trials LPA96 and LPA99 who presented with either molecular failure (MOLrel, n=16) or hematological relapse (HEMrel, n=36) was analyzed. Salvage therapy consisted of ATRA and high-dose ara-C-based chemotherapy (HDAC) in most cases (83%), followed by stem-cell transplantation (autologous, 18; allogeneic, 10; syngeneic, 1). Fourteen patients with MOLrel (88%) achieved second molecular complete response (molCR), whereas 81% HEMrel patients responded to second-line treatment, with 58% molCR. After median follow-up of 45 months, four MOLrel and 18 HEMrel patients, respectively, experienced a second relapse. Outcome after MOLrel compared favorably to HEMrel, with longer survival (5-year survival: 64+/-14 vs 24+/-8%, P=0.01) and lower relapse risk (5-year relapse risk: 30+/-13 vs 64+/-9%; P=0.044). Additionally, age <or=40 and male gender were favorable variables for survival, whereas molecular response predicted longer leukemia-free survival. In conclusion, early institution of salvage therapy at molecular failure, before onset of hematological relapse, is beneficial in APL. Moreover, given the poor outcome of HEMrel managed with ATRA and HDAC, use of alternative therapeutic strategies in this setting is warranted.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/blood
- Child
- Child, Preschool
- Combined Modality Therapy
- Cytarabine/administration & dosage
- Etoposide/administration & dosage
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Idarubicin/administration & dosage
- Kaplan-Meier Estimate
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/mortality
- Leukemia, Promyelocytic, Acute/pathology
- Leukemia, Promyelocytic, Acute/surgery
- Liposomes/administration & dosage
- Male
- Middle Aged
- Mitoxantrone/administration & dosage
- Neoplasm, Residual
- Oncogene Proteins, Fusion/blood
- Prognosis
- Recurrence
- Remission Induction
- Salvage Therapy
- Survival Analysis
- Time Factors
- Treatment Outcome
- Tretinoin/administration & dosage
Collapse
Affiliation(s)
- J Esteve
- Hospital Clínic, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Feusner J, Gregory JJ. Update on the management of pediatric acute promyelocytic leukemia. Clin Adv Hematol Oncol 2006; 4:854-5; author reply 855-6. [PMID: 17193721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
MESH Headings
- Adult
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Blood Component Transfusion
- Child
- Child, Preschool
- Female
- Hemorrhage/blood
- Hemorrhage/etiology
- Hemorrhage/mortality
- Hemorrhage/therapy
- Humans
- Leukemia, Myeloid, Acute/blood
- Leukemia, Myeloid, Acute/mortality
- Leukemia, Myeloid, Acute/therapy
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/complications
- Leukemia, Promyelocytic, Acute/mortality
- Leukemia, Promyelocytic, Acute/therapy
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
Collapse
|
43
|
Ninomiya M, Kajiguchi T, Yamamoto K, Kinoshita T, Emi N, Naoe T. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica 2006; 91:1571-2. [PMID: 17082016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023] Open
Abstract
Arsenic trioxide (ATO) has been used to treat acute promyelocytic leukemia (APL), but the oxidative DNA damage occurring in patients has not been fully elucidated. We measured 8-hydroxy-2'-deoxyguanosine (8-OHdG), one of the most abundant oxidative products of DNA, by enzyme-linked immunoassay, and reactive oxidative species (ROS), by luminol- and luminol-H2O2 chemiluminescence, in the plasma of four APL patients treated with ATO. After six courses of ATO therapy, the plasma 8-OHdG concentration had increased from 45.6+/-22.8 ng/mL to 310.2+/-239.6 ng/mL. The plasma chemiluminescence level did not change significantly. These findings suggest that ATO generates intracellular oxidative DNA damage, but this is not correlated with the plasma ROS level. The clinical significance of 8-OHdG during and after ATO therapy warrants further study.
Collapse
|
44
|
Braham-Jmili N, Sendi-Senana H, Labiadh S, Ben Abdelali R, Ben Abdelaziz A, Khelif A, Saad A, Kortas M. [Haematological characteristics, FAB and WHO classification of 153 cases of myeloid acute leukaemia in Tunisia]. Ann Biol Clin (Paris) 2006; 64:457-65. [PMID: 17040877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2006] [Accepted: 08/21/2006] [Indexed: 05/12/2023]
Abstract
A complete blood analysis with a careful morphologic examination of peripheral blood and bone morrow smears completed by cytochemical reaction will help to classify the most acute myeloid leukaemia (AML). Actually, the study of other cytogenetis and immunophenotypic markers are now necessary to confirm diagnosis. The World Health Organisation WHO classification (2001) incorporates theses approaches. The purpose of this study is a bio-clinical review according to the WHO recommendations in 153 cases of LAM diagnosed between January 1998 and December 2003. The patients were aged 2 months to 90 years with sex ratio (M/F) of 1,22. The morphologic conclusion was difficult in 12% cases. Presence of dysplasia is noted in 50% of cases with multilineage dysplasia in 42% of cases. Our results showed cloned chromosomal abnormalities in 57% of cases (t(8;21): 12%, t(15;17) : 10%, Inv16: 1,3%, 11q23: 2,6% et complex karyotype: 14,3%). In 69% of cases with multilineage dysplasia, the karyotype was normal. 3 cases of LAM were noted at patients treated for breast cancer with chirurgic chemotherapy and radiotherapy 3, 4 et 5 years after treatment (LAM3 with t(15;17), LAM4 with genetic abnormalities of chromosomes 3, 5, 7, 8, 9, 14 et 16 et LAM 6 with genetic abnormalities of chromosomes 4, 7, 12, 14, 19 et 21). In WHO classification, cytology is essential in diagnosis of LAM even if the karytype have an important prognostic value. Research of signs of dysplasia lineage after lineage constitutes an important microscopic work and it is difficult to quantify dysplasia when the lineage is poor.
Collapse
MESH Headings
- Acute Disease
- Adolescent
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Child
- Child, Preschool
- Chromosome Aberrations
- Diagnosis, Differential
- Female
- Humans
- Infant
- Karyotyping
- Leukemia, Erythroblastic, Acute/blood
- Leukemia, Erythroblastic, Acute/diagnosis
- Leukemia, Erythroblastic, Acute/genetics
- Leukemia, Myeloid/blood
- Leukemia, Myeloid/classification
- Leukemia, Myeloid/diagnosis
- Leukemia, Myeloid/genetics
- Leukemia, Myelomonocytic, Acute/blood
- Leukemia, Myelomonocytic, Acute/diagnosis
- Leukemia, Myelomonocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/diagnosis
- Leukemia, Promyelocytic, Acute/genetics
- Male
- Middle Aged
- Retrospective Studies
- Tunisia
- World Health Organization
Collapse
Affiliation(s)
- N Braham-Jmili
- Laboratoire d'Hématologie, CHU Farhat Hached, Sousse, Tunisie.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Breccia M, Avvisati G, Latagliata R, Carmosino I, Guarini A, De Propris MS, Gentilini F, Petti MC, Cimino G, Mandelli F, Lo-Coco F. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2006; 21:79-83. [PMID: 16932337 DOI: 10.1038/sj.leu.2404377] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Although the occurrence of thrombosis in acute promyelocytic leukemia (APL) has been reported during retinoic acid treatment, no studies carried out in large clinical cohorts have specifically addressed this issue. We analyzed 124 APL patients treated with the all-trans retinoic acid and idarubicin protocol and compared clinico-biologic characteristics of 11 patients who developed thrombosis with those of 113 patients who had no thrombosis. In seven patients, the events were recorded during induction, whereas in four patients deep vein thrombosis occurred in the post-induction phase. Comparison of clinico-biological characteristics of patients with and without thrombosis revealed in the former group higher median white blood cell (WBC) count (17 x 10(9)/l, range 1.2-56, P=0.002), prevalence of the bcr3 transcript type (72 vs 48%, P=0.01), of FLT3-ITD (64 vs 28%, P=0.02), CD2 (P=0.0001) and CD15 (P=0.01) expression. No correlation was found with sex, age, French-American-British subtype, all-trans-retinoic acid syndrome or with thrombophilic state that was investigated in 5/11 patients. Our findings suggest that, in APL patients consistent biologic features of leukemia cells may predict increased risk of developing thrombosis.
Collapse
MESH Headings
- Adult
- Aged
- Antibiotics, Antineoplastic/administration & dosage
- Antibiotics, Antineoplastic/adverse effects
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- CD2 Antigens
- Female
- Humans
- Idarubicin/administration & dosage
- Idarubicin/adverse effects
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/immunology
- Leukocyte Count
- Lewis X Antigen
- Male
- Middle Aged
- Mutation
- Predictive Value of Tests
- Risk Factors
- Tandem Repeat Sequences/genetics
- Thrombosis/chemically induced
- Thrombosis/genetics
- Thrombosis/immunology
- Tretinoin/administration & dosage
- Tretinoin/adverse effects
- fms-Like Tyrosine Kinase 3/genetics
Collapse
Affiliation(s)
- M Breccia
- Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Zhou J, Meng R, Sui XH, Meng L, Yang BF. Effects of arsenic trioxide administration styles on leukocytosis. Chin Med Sci J 2006; 21:111-4. [PMID: 16845799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
OBJECTIVE To study the effects of constantly slow intravenous arsenic trioxide (As2O3) infusion regimen on decreasing leukocytosis in vivo and in vitro. METHODS Three kinds of leukemia cells, NB4, K562, and acute promyelocytic leukemia (APL) cells, were cultured in the media with constant concentration and varying concentrations of As2O3 respectively for 24 hours. Seventy-five patients were enrolled in two groups randomly. In trial group, 37 patients received continuously slow intravenous As2O3 infusion regimen for 24 hours with an infusion rate of 8 drips per minute and total infusion duration of about 18-21 hours daily. In control group, 38 patients received routine regimen with an infusion rate of 45-55 drips per minute and total infusion duration of about 2-3 hours daily for 24 hours. The daily As2O3 dosage was 0. 16 mg/kg. The intracellular arsenic concentration was measured by atomic fluorescence assay. The apoptosis rate of cells, CD33- CD11b+ cells, and CD33+ CD11b- cells were monitored by flow cytometry. RESULTS The apoptosis rates of NB4, K562, and APL leukemia cells in the media with constant As2O3 concentration were 56.6% +/- 2.4%, 27.6% +/- 3.1%, and 52.2% +/- 2.8%, respectively, which were significantly higher than those with changing As2O3 concentration (23.2% +/- 2.1%, 11.0% +/- 2.5%, and 21.0% +/- 2.5%, respectively, P < 0.01). The apoptosis rates of APL, M2 type acute myeloid leukemia (AML-M2), and chronic myeloid leukemia (CML) patients in the trial group (28.5% +/- 1.9%, 9.5% +/- 0.6%, and 12.5% +/- 1.8%) were also significantly higher than those in control group (8.5% +/- 2.2%, 2. 9% +/- 0.8%, and 4.5% +/- 1.2%; P < 0.05). The ratios of CD33 CD11b- and CD33- CD11b+ cells in control group were significantly higher than those in trial group. CONCLUSION The continuously slow intravenous As2O3 infusion regimen can obtain high efficiency of apoptosis and low differentiation proportion, relieve leukocytosis, and gain maximal therapeutic benefit.
Collapse
MESH Headings
- Antineoplastic Agents/administration & dosage
- Apoptosis/drug effects
- Arsenic Trioxide
- Arsenicals/administration & dosage
- Cell Differentiation/drug effects
- Cell Line, Tumor
- Humans
- Infusions, Intravenous
- K562 Cells
- Leukemia/blood
- Leukemia/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myeloid, Acute/blood
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukocytosis/blood
- Leukocytosis/drug therapy
- Oxides/administration & dosage
Collapse
Affiliation(s)
- Jin Zhou
- Department of Internal Medicine, First Hospital of Harbin Medical University, Harbin 150001.
| | | | | | | | | |
Collapse
|
47
|
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107:3469-73. [PMID: 16373661 DOI: 10.1182/blood-2005-10-4006] [Citation(s) in RCA: 268] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We examined whether combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) might be an alternative to ATRA plus chemotherapy in untreated acute promyelocytic leukemia (APL). Twenty-five low-risk patients (white blood cell [WBC] count less than 10 × 109/L [10 000/μL]) received ATRA (45 mg/m2 daily) and ATO (0.15 mg/kg daily, beginning day 10 of ATRA), and in complete remission (CR) received ATO plus ATRA, without chemotherapy, unless they were reverse transcriptase–polymerase chain reaction (RT-PCR)–positive 3 months from CR date or had molecular relapse. Nineteen high-risk patients were treated identically, but received chemotherapy, generally 9 mg/m2 gemtuzumab ozogamycin (GO) on day 1 of induction. The CR rate was 39 of 44 (24 of 25 in low-risk, 15 of 19 in high-risk). Disease recurred at 9, 9, and 15 months, respectively, in 3 high-risk patients. The median follow-up time from CR date in the 36 patients alive in first CR is 16 months (15 months in low-risk, 20 months in high-risk), with 9 patients followed for at least 24 months. Each of the 36 patients was PCR-negative at last follow-up. Thus, none of the low-risk patients has received chemotherapy, and only 3 high-risk patients (the 3 with relapsed disease) have received chemotherapy past induction. ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL (eg, in older patients) and, when combined with GO, may improve outcome in high-risk patients.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Aminoglycosides/administration & dosage
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- Arsenic Trioxide
- Arsenicals/administration & dosage
- Arsenicals/adverse effects
- Female
- Gemtuzumab
- Humans
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukocyte Count
- Male
- Middle Aged
- Neoplasm Proteins/genetics
- Oncogene Proteins, Fusion/genetics
- Oxides/administration & dosage
- Oxides/adverse effects
- Polymerase Chain Reaction
- Remission Induction
- Tretinoin/administration & dosage
Collapse
Affiliation(s)
- Elihu Estey
- Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
48
|
Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107:2627-32. [PMID: 16352810 DOI: 10.1182/blood-2005-08-3532] [Citation(s) in RCA: 252] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AbstractArsenic trioxide, as a single agent, has proven efficacy in inducing molecular remission in patients with acute promyelocytic leukemia (APL). There is limited long-term outcome data with single-agent As2O3 in the management of newly diagnosed cases of APL. Between January 1998 to December 2004, 72 newly diagnosed cases of APL were treated with a regimen of single-agent As2O3 at our center. Complete hematologic remission was achieved in 86.1%. At a median follow-up of 25 months (range: 8-92 months), the 3-year Kaplan-Meier estimate of EFS, DFS, and OS was 74.87% ± 5.6%, 87.21% ± 4.93%, and 86.11% ± 4.08%, respectively. Patients presenting with a white blood cell (WBC) count lower than 5 × 109/L and a platelet count higher than 20 × 109/L at diagnosis (n = 22 [30.6%]) have an excellent prognosis with this regimen (EFS, OS, and DFS of 100%). The toxicity profile, in the majority, was mild and reversible. After remission induction, this regimen was administered on an outpatient basis. Single-agent As2O3, as used in this series, in the management of newly diagnosed cases of APL, is associated with responses comparable with conventional chemotherapy regimens. Additionally, this regimen has minimal toxicity and can be administered on an outpatient basis after remission induction.
Collapse
Affiliation(s)
- Vikram Mathews
- Department of Haematology, Christian Medical College and Hospital, Vellore 632004, India.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
De Vita S, De Matteis S, Laurenti L, Sorà F, Tarnani M, Cingolani A, Sica S. Acute promyelocytic leukemia in an HIV-infected patient: a case report. Am J Hematol 2006; 81:300. [PMID: 16550512 DOI: 10.1002/ajh.20553] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
MESH Headings
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antiretroviral Therapy, Highly Active/adverse effects
- Antiretroviral Therapy, Highly Active/methods
- Female
- HIV Seropositivity/blood
- HIV Seropositivity/complications
- HIV Seropositivity/drug therapy
- HIV-1
- Humans
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/complications
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/virology
- Middle Aged
Collapse
|
50
|
Au WY, Tam S, Fong BM, Kwong YL. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 2006; 107:3012-3. [PMID: 16554490 DOI: 10.1182/blood-2005-10-4175] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|